Polymun Scientific Immunbiologische Forschung Gmbh

Other

Chemap Ag

Katinger Gmbh

Pharmacia Biotech Ab

Vogelbusch Gesellschaft M.b.h.

Polymun Scientific Immunobilogische Forschung Gmbh

Polymun Scientific Immunbiogische Forschung Gmbh

Polynum Scientific Immunbiologische Forschung Gmbh

Polymun Scientific Immunobiologische Forschung Gmbh

Hermann W Katinger

Franz J Steindl

Thomas Muster

Alexandra Trkola

Martin Purtscher

Renate Kunert

Karola Vorauer-Uhl

Gottfried Himmler

Florian Ruker

Andrea Buchacher

Georg Maiwald

Winfried Scheirer

Manfred Reiter

Alois A Jungbauer

Robert Weik

Thomas Hemetsberger

Gerald Bluml

Theodor Gaida

Nicolaus Zach

Andreas Wagner

Claudia Ballaun

Wolfgang Ernst

Renate Predl

Gabriela Stiegler

Annelies Klima

Thomas Sterovsky

Christine Schmatz

Diethard Mattanovich

Reingard Grabherr

Julia Romanova

Boris Ferko

Andre Egorov

Dietmar Katinger

Roland Grunow

Hubertus Hohenblum

Tomas Porstmann

Ruediger Von Baehr

Stefan Naschberger

Bartold Rauschert

Johannes Grillari

Eckhard Furnschlief

Frantisek Franek

Guenter Kreismayr

Claus Riedl

Gunter Kreismayr

A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.

Recombinant human IgM-antibody effective against cancer cells

The invention relates to a pharmaceutical composition made from an active ingredient included in liposomes for topical application, whereby the liposomes have an aqueous medium in the interior thereof and contain at least one active ingredient therein which exerts a direct or indirect relaxing effect on smooth musculature and is preferably selected from the group of prostaglandins, adenylate cyclases, cAMP, AMP, ATP, NO-synthetases, nitrogen monoxide (NO), NO compounds, nitrates, guanylate cyclases, cGMP, GMP, GTP and phosphodiesterases, in particular, Sildenafil. The invention further relates to a method for production of said composition, optionally, in sterile form and the use of the liposomes supporting the active ingredient in various galenic forms for external application in the genital region, for prophylaxis and/or therapy of sexual disorders in men or women and/or for increase of sexual sensitivity.

Liposomal composition comprising an active ingredient for relaxing smooth muscle, the production of this composition and the therapeutic use thereof

The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HVI-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments thereof are directed against potently neutralizing anti-HIV-1 antibodies. The invention further relates to a hybridoma cell line 3H6 expressing the anti-idiotypic antibody and to pharmaceutical compositions containing the antibody or fragment thereof. The invention also relates to HIV-1 neutralizing Ab3-type antibodies elicited upon administration of the Ab2-type anti-idiotypic antibody or fragment thereof and to pharmaceutical compositions containing them. The invention also relates to the use of the present antibodies or fragments thereof as screening tools or as diagnostic or therapeutic agents.

Anti-idiotypic monoclonal antibody reactive with HIV neutralizing antibody 2F5

The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E10-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12. 4E10-IgG1 binds to a novel conserved epitope (NWFDIT) C-terminal of the ELDKWA epitope recognized by 2F5.1 appears that both epitopes are cryptic epitopes within a region that may be accessible in a virus-cell fusion intermediate state only. 4E10-IgG1 potently neutralizes tissue culture adapted strains but also primary isolates of different clades, including A, B, C, D, and E, inclusing viruses that were found to be resistant to 2F5. None of the tested isolates was resistant to both anti-gp41-antibodies. The invention therefore also relates to peptides containing the 4E10 epitope and to compositions made thereof, as well as to anti-idiotypic antibodies that are reactive with the paratope of 4E10-IgG1, to compositions containing an antiidiotypic antibody optionally in combination with a peptide containing the 4E10 epitope, and to anti-HIV-1 compositions comprising 4E10-IgG1, optionally in combination with another neutralizing antibody such as 2F5 and/or 2G12.

IGG1 monoclonal antibody with anti-HIV neutralizing activity

The invention relates to a simple and efficient process for isolating viruses from various sources and for producing live attenuated influenza vaccines in a serum-free Vero cell culture under conditions where alterations in the surface antigens of the virus due to adpative selection are minimized or prevented. The process does not require purification of the virus-containing supernatant harvested from the cell culture nor post-incubation treatment of the viruses for HA activation. The invention further relates to influenza A and B master strain candidates and to vaccines made thereof.

Live attenuated influenza vaccine

The present invention relates to a method for the manufacture and purification of recombinant trypsinogen and trypsin inand yeast, using high yield expression vectors with and without secretion leader sequences. The invention further relates to an improved method and apparatus for carrying out protein refolding specifically useful for processing trypsinogen that has accumulated intracellularly in the form of inclusion bodies.

Method for the manufacture of recombinant trypsin

The present invention relates to cell-regulatory proteins and to nucleotide sequences encoding said proteins wherein the proteins have been found to be potential tumor and/or senescense markers useful for medical diagnostics and additionally having therapeutical potential as well as antiapoptotic properties useful for improving cell viability in cell culture technology. The invention further relates to antibodies directed against the cell-regulatory proteins and to their use in medical diagnostics and therapy. The invention further relates to methods for the manufacture and application of the cell-regulatory proteins and of the corresponding nucleotide sequences.

Tumor and senescence marker

The invention relates to short 3- to 10-mer bioactive oligopeptides composed of amino acid residues selected from the group consisting of glycine, alanine, &#x3b2;-alanine, serine, histidine, glutamic acid, aspartic acid, lysine and arginine. They are able to improve at least one cell culture parameter such as growth rate, viable cell number, viability on day 6 or 7, or final product yield, when added to the basal nutrient medium. The invention further relates to mixtures of such oligopeptides and to a method of improving cell culture parameters by incubating animal or plant cells in the presence of said oligopeptides.

Bioactive oligopeptides

The invention relates to a device for producing lipid vesicles, which is equipped with a line () for transporting a polar liquid phase, with a line () for transporting an organic liquid phase containing lipids, with a collecting receptacle () for accommodating produced lipid vesicles, and with means for conveying the liquid phases through lines () and (). At at least one location, the outer side of line () forms a common contact surface with line () inside of which a common opening () is provided that permits the flow of liquid and joins the inside of line () to the inside of line (). Lines () and () do not contain agitating or dispersing aids in the area of the opening (). The invention also relates to a method for the careful production of lipid vesicles, wherein the lipid phase is sprayed under pressure perpendicular to the direction of flow of the polar phase and into the same, whereupon lipid vesicles having a narrow size distribution form spontaneously and without the action of mechanical agitating or dispersing aids.

Method and device for producing lipid vesicles

Superoxide dismutase (SOD), preferably rhSOD, is used in liposomes, optionally mixed with hyaluronic acid and/or at least one physiologically acceptable carrier, and other optional additives, to prepare a pharmaceutical composition useful against increased concentrations of superoxide radicals and/or the damage caused thereby. The compositions are administered topically, preferably as gels or ointments, to prevent and/or heal human fibrotic tissue degeneration diseases, in particular induratio penis plastica (Peyronie's Disease).

Liposomal recombinant human superoxide-dismutase for the treatment of peyronie's disease

Disclosed are antibodies which can be used for the manufacture of vaccines for active and/or passive immunization of persons in need of such treatment. The invention also provides for human monoclonal antibodies that are functionally equivalent to the above-mentioned antibodies produced by any one of the cell lines CL1 through CL6 (deposited at the European Collection of Animal Cell Cultures (ECACC) at the PHLS in Porton Down, Salisbury, UK). Also provided are hybridoma and/or CHO cell lines producing any one of the antibodies disclosed and claimed herein, Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention and/or therapeutical treatment of HIV-1 infections in vitro and in vivo.

HIV-vaccines

Application of SOD in liposomes

Disclosed are antibodies which can be used for the manufacture of vaccines for active and/or passive immunization of persons in need of such treatment. The invention also provides for human monoclonal antibodies that are functionally equivalent to the above-mentioned antibodies produced by any one of the cell lines CL1 through CL6 (deposited at the European Collection of Animal Cell Cultures (ECACC) at the PHLS in Porton Down, Salisbury, UK). Also provided are hybridoma and/or CHO cell lines producing any one of the antibodies disclosed and claimed herein. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention and/or therapeutical treatment of HIV-1 infections in vitro and in vivo.

This invention concerns peptides binding to antibodies which show neutralizing activity against different strains and clinical isolates of HIV-1 and which inhibit the fusion of cells infected with HIV-1. These peptides are combined with an adjuvant, as recombinant fusion proteins, chemically coupled to carrier molecules, as recombinant chimeric viruses or as recombinant antibodies.

Peptides that induce antibodies which neutralize genetically divergent

Growing community of inventors

Vienna, Austria

Hermann W Katinger